Development and pharmacological evaluation of an intranasal liposomal norbinaltorphimine formulation for the prevention of pain-induced negative affect
Jesús David Lorente, Yolanda Campos‐Jurado, Miquel Martínez‐Navarrete, Javier Cuitavi, Marta Cervera-Sospedra, Jessica A. Higginbotham, Ana Melero, Ana Polache, Antonio José Guillot, Jose Moron, Lucía Hipólito
This paper develops an intranasal liposomal NorBNI formulation that selectively delivers KOR antagonists to the brain, reducing systemic exposure and off-target effects while improving pain-induced negative affect.
bioRxiv · Sep 1, 2026 · PreprintNeuroscience